Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has shared an update.
Hikma Pharmaceuticals has confirmed that, as of 31 March 2026, its issued share capital consists of 217,930,179 ordinary shares of 10 pence each with voting rights, excluding 12,833,233 shares held in treasury that carry no voting rights. The updated share count provides the official denominator for investors and other stakeholders to calculate regulatory disclosure thresholds for changes in their holdings under U.K. transparency rules, ensuring accurate reporting of significant share interests.
By clarifying its total voting rights, Hikma is helping maintain compliance with financial market regulations and supporting transparency in its shareholder base. The announcement has practical implications for institutional investors, funds and other market participants who must monitor and report their positions relative to disclosure limits set by the Financial Conduct Authority.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company that manufactures and markets a broad range of generic and branded medicines. The group focuses on supplying injectable, oral and specialty pharmaceutical products to hospitals, pharmacies and healthcare providers across global markets, with a strong presence in the U.K., MENA and U.S. generics segments.
Average Trading Volume: 1,342,361
Technical Sentiment Signal: Sell
Current Market Cap: £2.74B
See more insights into HIK stock on TipRanks’ Stock Analysis page.